Polymeric nanomedicine for cancer MR imaging and drug delivery

被引:142
作者
Khemtong, Chalermchai [1 ]
Kessinger, Chase W. [1 ]
Gao, Jinming [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA
基金
美国国家卫生研究院;
关键词
IRON-OXIDE NANOPARTICLES; PEGYLATED LIPOSOMAL DOXORUBICIN; MESOPOROUS SILICA NANOPARTICLES; PLURONIC((R)) BLOCK-COPOLYMERS; GLYCOL CHITOSAN NANOPARTICLES; NONVIRAL GENE DELIVERY; SMALL INTERFERING RNA; CONTRAST AGENTS; IN-VIVO; PARACEST AGENTS;
D O I
10.1039/b821865j
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Multifunctional nanomedicine is emerging as a highly integrated platform that allows for molecular diagnosis, targeted drug delivery, and simultaneous monitoring and treatment of cancer. Advances in polymer and materials science are critical for the successful development of these multi-component nanocomposites in one particulate system with such a small size confinement (<200 nm). Currently, several nanoscopic therapeutic and diagnostic systems have been translated into clinical practice. In this feature article, we will provide an up-to-date review on the development and biomedical applications of nanocomposite materials for cancer diagnosis and therapy. An overview of each functional component, i.e. polymer carriers, MR imaging agents, and therapeutic drugs, will be presented. Integration of different functional components will be illustrated in several highlighted examples to demonstrate the synergy of the multifunctional nanomedicine design.
引用
收藏
页码:3497 / 3510
页数:14
相关论文
共 143 条
  • [31] In vivo imaging of quantum dots encapsulated in phospholipid micelles
    Dubertret, B
    Skourides, P
    Norris, DJ
    Noireaux, V
    Brivanlou, AH
    Libchaber, A
    [J]. SCIENCE, 2002, 298 (5599) : 1759 - 1762
  • [32] DUNCAN R, 1984, ADV POLYM SCI, V57, P51
  • [33] The dawning era of polymer therapeutics
    Duncan, R
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) : 347 - 360
  • [34] POLYMER CONJUGATES - PHARMACOKINETIC CONSIDERATIONS FOR DESIGN AND DEVELOPMENT
    DUNCAN, R
    SPREAFICO, F
    [J]. CLINICAL PHARMACOKINETICS, 1994, 27 (04) : 290 - 306
  • [35] Cancer nanotechnology: Opportunities and challenges
    Ferrari, M
    [J]. NATURE REVIEWS CANCER, 2005, 5 (03) : 161 - 171
  • [36] MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents
    Funovics, MA
    Kapeller, B
    Hoeller, C
    Su, HS
    Kunstfeld, R
    Puig, S
    Macfelda, K
    [J]. MAGNETIC RESONANCE IMAGING, 2004, 22 (06) : 843 - 850
  • [37] Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies
    Gabizon, A
    Shmeeda, H
    Barenholz, Y
    [J]. CLINICAL PHARMACOKINETICS, 2003, 42 (05) : 419 - 436
  • [38] Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy
    Gabizon, AA
    [J]. CANCER INVESTIGATION, 2001, 19 (04) : 424 - 436
  • [39] Hyperbranched polymers: from synthesis to applications
    Gao, C
    Yan, D
    [J]. PROGRESS IN POLYMER SCIENCE, 2004, 29 (03) : 183 - 275
  • [40] Sensitivity enhancement by exchange mediated magnetization transfer of the xenon biosensor signal
    Garcia, Sandra
    Chavez, Lana
    Lowery, Thomas J.
    Han, Song-I
    Wemmer, David E.
    Pines, Alexander
    [J]. JOURNAL OF MAGNETIC RESONANCE, 2007, 184 (01) : 72 - 77